• Standardized Whole-Blood Stimulation Reveals Metabolic Contr

  2026-07-07

  This study introduces a robust protocol for standardized whole-blood stimulation with metabolic modulation, enabling large-scale analysis of how cellular metabolism shapes immune responses. The approach allows precise dissection of cytokine regulation by metabolic pathways and opens new avenues for immunometabolic research and therapeutic development.

• Cardiogreen (Indocyanine Green): Advanced Workflows & Troubl

  2026-07-07

  Cardiogreen (Indocyanine Green) empowers translational research with high-fidelity vascular diagnostics and precise apoptosis induction in photodynamic therapy. Integrated protocols and troubleshooting strategies help maximize reliability in cardiac, hepatic, and oncology workflows.

• JHU-083: 6-diazo-5-oxo-L-norleucine Precursor for Neuro-Redo

  2026-07-06

  JHU-083, a potent 6-diazo-5-oxo-L-norleucine precursor, enables precise modulation of glutaminase activity in neurological and redox models. Its robust selectivity and solubility make it an indispensable tool for dissecting glutamate pathways in experimental cerebral malaria and glutamate excitotoxicity research.

• Gepotidacin: Redefining Antibacterial Innovation for Resista

  2026-07-06

  This thought-leadership article dissects Gepotidacin’s breakthrough mechanism, clinical promise, and strategic value for translational researchers confronting antibiotic resistance. By synthesizing recent mechanistic and clinical insights, the article delivers actionable guidance for scientists aiming to advance antibacterial research and develop next-generation therapeutics.

• Cy3 Goat Anti-Rabbit IgG (H+L) Antibody: Protocols & QC Guid

  2026-07-05

  The Cy3 Goat Anti-Rabbit IgG (H+L) Antibody enables sensitive and specific detection of rabbit primary antibodies in immunofluorescence, immunohistochemistry, and related fluorescence-based assays. This reagent is suitable where reliable signal amplification and minimal cross-reactivity are critical. It is not recommended for diagnostic or medical use, and its performance is limited to workflows utilizing rabbit IgG primaries.

• Gepotidacin Phase III Trials for uUTI: Design, Rationale, an

  2026-07-04

  The referenced phase III trials represent one of the largest, rigorously designed clinical investigations of Gepotidacin (GSK2140944) for uncomplicated urinary tract infections (uUTIs) in women. By directly comparing this novel topoisomerase inhibitor to nitrofurantoin, the studies address critical gaps in oral antibiotic options amid rising resistance, with significant implications for antibacterial research and clinical practice.

• Gepotidacin (GSK2140944): Next-Gen Tools for Antibacterial R

  2026-07-03

  Gepotidacin (GSK2140944) empowers antibiotic resistance research with a unique mechanism targeting bacterial topoisomerases, unlocking new experimental workflows against multidrug-resistant pathogens. This article translates cutting-edge findings into actionable protocols, troubleshooting insights, and practical advances for translational researchers leveraging APExBIO’s Gepotidacin.

• CD28-ARS2 Axis Regulates PKM Splicing for T Cell Tumor Immun

  2026-07-03

  The referenced study uncovers how the CD28-ARS2 signaling axis in CD8+ T cells drives alternative splicing of the PKM gene, promoting metabolic flexibility critical for antitumor responses. This mechanistic insight deepens our understanding of immunometabolism and suggests new translational strategies for targeting T cell function in oncology.

• Early Pheromone Cues Accelerate Neurodegeneration in C. eleg

  2026-07-02

  Peng et al. (2023) demonstrate that perception of specific pheromones during early development in C. elegans remodels neurodevelopment and triggers neurodegeneration in adulthood. This work reveals a mechanistic link between environmental chemical cues, neural circuit remodeling, and proteostasis disruption, offering new insights for neurodegeneration research.

• ONX-0914 (PR-957): Selective Immunoproteasome Inhibition in

  2026-07-02

  ONX-0914 (PR-957) is a potent, selective immunoproteasome inhibitor that targets the LMP7 (β5i) subunit, modulating cytokine production and immune responses. It has demonstrated efficacy in models of autoimmune and inflammatory diseases, with well-characterized selectivity and workflow parameters.

• DMH-1 (B3686): Deep Mechanistic Insights for ALK2 Inhibition

  2026-07-01

  Explore how DMH1, a selective ALK2 inhibitor, enables mechanistic dissection of BMP signaling in organoid and non-small cell lung cancer research. This article offers advanced protocol insights and a critical analysis of recent breakthroughs in human organoid modeling and BMP pathway modulation.

• SR 11302: Applied AP-1 Transcription Factor Inhibitor Workfl

  2026-07-01

  SR 11302 brings selective AP-1 transcription factor inhibition to cancer research, enabling targeted suppression of tumorigenic pathways without the side effects of retinoids. Discover how this compound powers precise experimental design, advanced immunomodulation, and robust troubleshooting in both cellular and animal models.

• Dual-Action p38α MAPK Inhibitors Enhance Dephosphorylation D

  2026-06-30

  The reference study demonstrates that certain kinase inhibitors, including ATP-competitive compounds, not only block p38α MAPK activity but also accelerate its dephosphorylation by phosphatases. This dual-action mechanism provides a new structural and functional framework for designing more selective and potent inhibitors, with implications for inflammation, diabetes, and neuroregeneration research.

• TRPV1+ Nerve Stimulation Suppresses Inflammation via Reflex

  2026-06-30

  The referenced iScience study demonstrates that targeted stimulation of TRPV1+ peripheral somatosensory nerves, including with capsaicin analogs like Nonivamide, suppresses systemic inflammation via somato-autonomic reflexes. This mechanistic insight provides a foundation for novel research strategies targeting neuroimmune modulation.

• Z-WEHD-FMK: Irreversible Caspase Inhibitor for Inflammation

  2026-06-29

  Z-WEHD-FMK (Z-Trp-Glu(OMe)-His-Asp(OMe)-FMK) is a potent, cell-permeable inhibitor of caspase-1, -4, and -5. It enables precise, irreversible blockade of inflammatory caspase signaling in cell biology and infectious disease research. This article details its mechanism, benchmarks, and laboratory applications, highlighting evidence-based best practices.

14791 records 1/987 page Next 12345 下5页 Last page